Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (107 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientspatienttherapystandardstatus
  Phrases that lowered it: trialdisorderobjectiverelevantterm
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 26.7% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 2/3 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 16985 (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Keywords listed: 6 (lowers risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Intra-arterial TNK Following Endovascular Thrombectomy in Patients With Large Vessel Occlusion of Posterior Circulation NCT05684172 · started 2023 · scored riskier than 74% of active trials completed
• Intraarterial Alteplase Versus Placebo After Mechanical Thrombectomy NCT03876119 · started 2018 · scored riskier than 82% of active trials completed
• Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion NCT05701956 · started 2023 · scored riskier than 72% of active trials completed
• CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2). NCT05797792 · started 2023 · scored riskier than 80% of active trials completed
• Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion NCT04454788 · started 2020 · scored riskier than 86% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.